Find a TenderClosedTender notice
Published 15 Jan 2026, 09:42 GMT

Official UK procurement notice

Medicines Licensing Assessor Services

Official notice

Authority: MHRA (Central government)

Framework agreement3 lotsServicesOpen procedureAbove thresholdSME suitable
Framework ceiling (notional)£10,000,000total for 3 lots · framework ceiling, not attributable revenue · 1 value update
Submissions closed 6 Aug 2026
Lots 3see the lot list below
Framework period 3 yrsends 15 Oct 2029 · up to 15 Oct 2030 with extensions · starts 16 Oct 2026

What is being bought3 lots · detail below

Published requirement description

The Medicines and Healthcare products Regulatory Agency is the regulator of medicines, medical devices and blood components for transfusion in the UK. MHRA carries out a wide range of activities to fulfil its role as a patient safety regulator. This includes carrying out assessments of the safety, quality and efficacy of medicines, assessing the safety of proposed clinical trials of medicines and medical devices, inspecting the premises of those manufacturing, supplying or distributing medicines and monitoring the ongoing safety of all medical products, taking swift action where necessary to prevent harm to patients. The MHRA also engages with companies within the regulated sector to provide specific, scientific advice on the development of products. The aim of such advice is to ensure the developer understands the requirements of the regulator, ensuring that the developer can provide the required information to support a properly informed assessment.

With a wide range of critical deliverables, MHRA is seeking opportunities to add to its traditional in-house expertise through the establishment of additional sources of both capacity and capability. These will enable MHRA to deliver innovative, new and improved services at increased pace, safeguarding public health and supporting the growth of life sciences in the UK.

MHRA is seeking suppliers with the capacity and capability to deliver assessments of complex clinical and non-clinical regulatory data and provide carefully evidenced judgements within an MHRA assessment and quality assurance framework. Such assessments may relate to marketing authorisation applications, clinical trial applications and a variety of other compliance activities. Deployment of supplier resources will be on a flexible basis to enable MHRA greater discretion in flexing established capacity as needed to support increased growth in UK life sciences through new and improved advice and support services.

To achieve this ambition, MHRA wishes to establish a framework of specialist providers, which cover 3 Lots. Up to four suppliers, who meet the minimum criteria, may be awarded a place on each Lot.

Lot 1: Pharmaceutical Assessment: Assessment of pharmaceutical/quality data (in compliance with Module 3 and Module 2 (sections relevant to Quality) of the Common Technical Document).

Lot 2: Medical Assessment: Assessment of clinical, statistical and clinical pharmacology data (in compliance with Module 5 and Module 2 (sections relevant to Clinical) of the Common Technical Document).

Lot 3: Non-Clinical Assessment: Assessment of non-clinical data (in compliance with Module 4 of the Common Technical Document).

CPV: Medical analysis services · Research and development services and related consultancy services

How this framework works

From the published notice
Type
Closed framework
Call-offs
call-offs may be awarded directly or by further competition
Places
up to 12 suppliers
Framework period
3 yrs · up to 4 yrs from 16 Oct 2026
Published description of the framework

The Framework Contract Call Off Process may use:

Mini Competition

Request for Quotation

Award without Competition

Lots and requirements (3)Procurement structure

3 lots · all with a published value · evaluation weights differ by lot
Lot #1Pharmaceutical AssessmentRenewal 3 yrsSMEPublished value£5,000,000

Assessment of pharmaceutical/quality data (in compliance with Module 3 and Module 2 (sections relevant to Quality) of the Common Technical Document).

Contract period: 16 Oct 2026 – 15 Oct 2029 (3 yrs) · up to 15 Oct 2030 with extensionsValue: £5,000,000 exc. VAT · £6,000,000 inc. VAT
Delivery: UKEligibility: SME eligible
Extensions: The MHRA has the option to extend the Framework Contract by up to 1 year.
Lot #2Medical AssessmentRenewal 3 yrsPublished value£4,000,000

Assessment of clinical, statistical and clinical pharmacology data (in compliance with Module 5 and Module 2 (sections relevant to Clinical) of the Common Technical Document).

Contract period: 16 Oct 2026 – 15 Oct 2029 (3 yrs) · up to 15 Oct 2030 with extensionsValue: £4,000,000 exc. VAT · £4,800,000 inc. VAT
Extensions: The MHRA has the option to extend the Framework Contract by up to 1 year.
Lot #3Non-Clinical AssessmentRenewal 3 yrsPublished value£1,000,000

Assessment of non-clinical data (in compliance with Module 4 of the Common Technical Document).

Contract period: 16 Oct 2026 – 15 Oct 2029 (3 yrs) · up to 15 Oct 2030 with extensionsValue: £1,000,000 exc. VAT · £1,200,000 inc. VAT
Extensions: The MHRA has the option to extend the Framework Contract by up to 1 year.

What it takes to win
i

How this buyer will score bids.

The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).

Evaluation split and conditions of participation as published; the tender pack may add more
How bids were scored

Lots publish different evaluation splits; there is no single procedure weighting.

LotQualityPriceSocial valueSplit
1 · Pharmaceutical Assessment60%30%10%
2 · Medical Assessment60%30%10%
3 · Non-Clinical Assessment60%30%10%
Lot distribution rule: Lot 1: Pharmaceutical Assessment: Assessment of pharmaceutical/quality data (in compliance with Module 3 and Module 2 (sections relevant to Quality) of the Common Technical Document). Lot 2: Medical Assessment: Assessment of clinical, statistical and clinical pharmacology data (in compliance with Module 5 and Module 2 (sections relevant to Clinical) of the Common Technical Document). Lot 3: Non-Clinical Assessment: Assessment of non-clinical data (in compliance with Module 4 of the Common Technical Document).
What this means for your bid
  • Price carries 30 points on every lot: a 10% discount moves about 3 points.
  • “Medicines Licensing Assessor Services” is a framework: the contest is a place on its panel, up to 12 suppliers, not a single contract: call-offs may be direct or by further competition.

Price arithmetic assumes straight proportional scoring; the tender pack may use another formula.

Procedure terms & legal framework

From the official record
Procedure method
Open procedure
Legal basis
UKPGA · 2023/54 Procurement Act 2023
Procurement category
Services
Notice status
Closed
Procurement threshold
Above threshold (FTS publication)
Regulatory regime
Standard
Commercial structure
Framework agreement
Who may use this agreement
Not stated in the notice; call-off rights may be limited to the establishing authority
Competition type
Competitive procedure
GPA / WTO covered
Unspecified in notice
Recurring procurement
Unspecified in notice
First published
15 Jan 2026, 09:42 GMT
Last source update
3 Jul 2026, 07:48 BST
Award evaluation window
Submission end – 1 Oct 2026
Authority reference
C456102
FTS notice number
2026/S 000-061976
Latest notice
Tender notice (UK4)
Classification (CPV)
Medical analysis servicesResearch and development services and related consultancy services
Delivery area
UK
Official registry OCID
ocds-h6vhtk-060643 Find a Tender

How it was run

Official notice
Run through: Atamis (Health Family) · Who buys & how to bid on Atamis
Supplier login requiredElectronic submission allowedLanguage: EN
Access & registration note: Free · one account PER buying organisation portal · password resets come "from Salesforce.com" (check spam)
Appointment period ends
6 Aug 2026, 12:00 BST
Clarification deadline
21 Jul 2026, 12:00 BST
Submission channel
Official e-sourcing portal
Electronic submission
Allowed
Accepted languages
en
Detailed submission instructions & authority contactsFrom official release

Bidders should access the Health Family e-tendering portal to access the full-set of requirements and to submit any tender.

Interested suppliers atamis-1928.my.site.com/s/Welcome ↗

Timeline

15 Jan 2026 → 16 Oct 2026 · 9 dates
  1. Planning notice published285 days ago
    15 Jan 2026, 09:42 GMT
  2. Market engagement276 days ago
    23 Jan 2026, 23:59 GMT

    MHRA will hold a virtual pre-market engagement event on Monday 26th January at 2pm inviting suitably qualified and experienced suppliers to attend a presentation by the Healthcare Quality and Access team where high-level information about the requirements will be shared followed by an opportunity to participate in a Q&A session.

    The objective of this session will be to:

    • Understand supplier appetite and opinion and gain an understanding on the viability of the concept
    • Understand barriers, risks and issues and any potential innovative solutions
    • Inform a high-quality specification, procurement strategy and the structure of the contract/framework

    Suppliers are also invited to express their interest in a separate 1:1 engagement session immediately following the event to share any useful intelligence. Requests will be accommodated based on capacity and no guarantees are made.

    Suppliers attending the event will not have any advantage over organisations who do not participate, and this market consultation is in no way a guarantee of future work. Material shared at this event including a summary of the Q&A will be made available as part of any future tender pack ensuring all participating suppliers have access to the same information.

    Suppliers wishing to attend the event should email [email protected] to receive joining instructions.

  3. Next notice expected238 days ago
    2 Mar 2026, 23:59 GMT
  4. Tender notice published117 days ago
    1 Jul 2026, 18:18 BST
  5. Latest notice published116 days ago
    3 Jul 2026, 07:48 BST
  6. Clarification questions by97 days ago
    21 Jul 2026, 12:00 BST
  7. Admission / appointment period ends81 days ago · period end, not a bid countdown
    6 Aug 2026, 12:00 BST
  8. Award decision expected by25 days ago
    1 Oct 2026, 23:59 BST
  9. Contract starts11 days ago
    16 Oct 2026, 00:00 BST

Notice history

7 events · 3 releases on Find a Tender · since 15 Jan 2026
  1. Preliminary market engagement notice published
    15 Jan 2026, 09:42 GMT
    UK2
  2. Tender notice published
    1 Jul 2026, 18:18 BST
    UK4
  3. Published value published: £10,000,000
    1 Jul 2026, 18:18 BST
  4. Status changed to active
    1 Jul 2026, 18:18 BST
  5. Procurement method changed
    1 Jul 2026, 18:18 BST
  6. Deadline published: 6 Aug 2026, 12:00 BST
    1 Jul 2026, 18:18 BST
  7. Tender notice published
    3 Jul 2026, 07:48 BST
    UK4
Published amendments (1)

Amendment to internal reference.

Contracting authority & participating public bodies

MHRA

Contracting authorityPublic authority - central government GB-PPON: PJLJ-9824-VXPG 10 South Colonnade, Canary Wharf, London, London, E14 4PUContact name, email

Official documents & specifications (3)

Official links; attachments are not copied

Notices published for this procedure

  • Tender notice tenderTender noticeUK4Tender notice on Find a Tender
  • Tender notice tenderTender noticeUK4Tender notice on Find a Tender
  • Preliminary market engagement notice planningPreliminary market engagement noticeUK2Preliminary market engagement notice on Find a Tender